非酒精性脂肪性肝病(NAFLD)是世界范围内慢性肝病的一个主要原因,约15%的NAFLD患者会发展为非酒精性脂肪性肝炎、肝纤维化、肝硬化甚至肝癌。目前其发病及进展机制尚未明确,也无有效治疗手段。因此,构建临床前NAFLD动物模型至关重要,有助于为NAFLD提供临床治疗的新方案。本文将系统分析目前已构建的NAFLD动物模型在临床前研究中的局限性,并重点总结和综述基于基因编辑在NAFLD动物模型构建中的应用及研究进展,这对于探讨NAFLD发病机制及新药研发具有重要的临床意义。

Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease worldwide, and about 15% of NAFLD patients will develop into nonalcoholic steatohepatitis, hepatic fibrosis, cirrhosis, and ultimately hepatocellular carcinoma. However, the biological mechanism of the pathogenesis and progression of NAFLD is not fully understood, and there are still no effective or targeted therapies for NAFLD. Therefore, it is an urgent need to construct pre-clinical animal models of NAFLD, which will help to better understand and explore the potential therapeutic strategy in the treatment of NAFLD. Here, we summarize the recent advances and limitations of the established animal models of NAFLD and focus on the potential application and research progress of genome editing for constructing the animal models of NAFLD. There animal models will be very useful to reveal the pathologic mechanism of human NAFLD, and to screen new therapeutic drugs.

       结直肠癌（CRC）是全球第三大最常见的癌症，也是癌症相关死亡的第二大常见原因。结直肠癌肝转移（CRLM）是导致CRC患者死亡的主要原因，根治性肝切除术是目前有望治愈CRLM的唯一途径，但大部分患者不能进行根治性肝切除术。通过早期发现并进行针对性干预，能够改善患者的治疗效果及预后。文章通过综述CRLM的发病机制、诊疗现状及最新纳米诊疗方法，为深入探索高效诊疗方法提供思路。

      Colorectal cancer（CRC）is the third most common cancer and the second most common cause of cancer-related death worldwide．Colorectal cancer liver metastases（CRLM）are the leading cause of death in patients with CRC．Radical hepatectomy is the only way to cure CRLM so far，while most patients cannot undergo radical hepatectomy．CRLM treatment efficacy and prognosis can be improved by early diagnosis and specialized intervention．This paper reviews the pathogenesis，diagnosis，and treatment status of CRLM and the latest nano-diagnosis and treatment methods so as to provide ideas for in-depth exploration of efficient diagnosis and treatment methods．